Abstract
The prevention and treatment of coronary heart disease is a major challenge in the overall management of the patient with type 2 diabetes. Diabetic dyslipidaemia is an important risk factor and is open to therapeutic intervention. However, as yet there are no primary or secondary coronary heart disease prevention trials of lipid-lowering therapy reported in diabetic populations. In this review, on-going clinical trials of lipid-lowering therapy in specific diabetic populations will be described.
| Original language | English |
|---|---|
| Pages (from-to) | 621-626 |
| Number of pages | 6 |
| Journal | Current Opinion in Lipidology |
| Volume | 11 |
| Issue number | 6 |
| Publication status | Published - Dec 2000 |
